
iRadimed fell 0.1% from $85.42 to $85.35, behind the S&P 500's +13.3%. Its worst day was Oct 30 (−10.6%), and its low came Oct 30 at $76.68.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.54 beat the $0.46 estimate on $22.7M revenue (est. $21.7M); Q1 revenue guidance of $21.0M–$22.0M against the $20.8M consensus.
+9.6%, the year's best day · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
EPS of $0.49 beat the $0.44 estimate on $22.0M revenue (est. $21.4M); FY revenue guidance of $91.0M–$96.0M against the $92.4M consensus.
+4.4%, on 347K shares, the year's heaviest volume · S&P 500 +0.3%
iRadimed shares fell 6.2%, while the S&P 500 rose 0.4%.
−6.2% · S&P 500 +0.4%
EPS of $0.46 beat the $0.44 estimate on $20.5M revenue (est. $20.4M); FY revenue guidance of $91.0M–$96.0M against the $91.2M consensus.
−4.6% · S&P 500 +0.7%
EPS of $0.55 beat the $0.54 estimate on $24.2M revenue (est. $23.4M); FY revenue guidance of $91.6M–$93.1M against the $92.1M consensus.
−10.6%, the year's worst day · S&P 500 −1.8%
Where it ended: a close of $85.35 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 9, 2027 (EPS est. $0.58, revenue est. $25.6M).
As of the Nov 13, 2026 close
Replay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IRMD and SPY from Benzinga historical bars. Not investment advice.